CO4910137A1 - Combinaciones antivirales - Google Patents

Combinaciones antivirales

Info

Publication number
CO4910137A1
CO4910137A1 CO97034780A CO97034780A CO4910137A1 CO 4910137 A1 CO4910137 A1 CO 4910137A1 CO 97034780 A CO97034780 A CO 97034780A CO 97034780 A CO97034780 A CO 97034780A CO 4910137 A1 CO4910137 A1 CO 4910137A1
Authority
CO
Colombia
Prior art keywords
amino
purin
cyclopropylamino
zidovudine
cis
Prior art date
Application number
CO97034780A
Other languages
English (en)
Inventor
Clair Martha Heider St
David Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614024.9A external-priority patent/GB9614024D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4910137A1 publication Critical patent/CO4910137A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una combinación, que comprende ácido 3S-[3R* (1R* ,2S* )]-[3-[[(4-aminofenil)sulfonil](2 metilpropil)-amino]-2- hidroxi-1-fenil-metil)propil]carbámico, tetrahidro- 3-furanil éster, zidovudina y (1S, 4R)-cis-4-[2- amino-6-(ciclopropilamino)-9H-purin-9-il]-2- ciclopenten-1-metanol. Una combinación, que comprende dos compuestos seleccionados del ácido 3S-[3R* (1R* ,2S* )]-[3-[[(4aminofenil)sulfonil](2-metilpropil)-amino]-2- hidroxi-1-fenil-metil)propil]carbámico, tetrahidro-3-furanil éster, zidovudina, y (1S, 4R)-cis-4-[2-amino-6-(ciclopropilamino)9H-purin-9-il]-2-ciclopenten-1-metanol siempre que los dos compuestos no sean zidovudina y (1S, 4R)-cis-4-[2-amino-6-(ciclopropilamino)-9H-purin-9- il]-2-ciclopenten-1-metanol.Una combinación, que comprende dos compuestos seleccionados del ácido 3S-[3R* (1R* ,2S* )]-[3-[[(4- aminofenil)sulfonil](2-metilpropil)-amino]-2-hidroxi-1-fenilmetil)propil]-carbámico, tetrahidro-3-furanil éster o un derivado fisiológicamente funcional de los mismos, zidovudina o un derivado fisiológicamente funcional de la misma, y (1S, 4R)-cis-4-[2-amino-6-(ciclopropilamino)- 9H-purin-9-il]-2-ciclopenten-1-metanol o un derivado fisiológicamente funcional del mismo.Una combinación de acuerdo a la reivindicación 2, que comprende ácido 3S-[3R* (1R* ,2S* )]-[3-[[(4-aminofenil)sulfonil](2-metilpropil)-amino]-2- hidroxi-1-fenil-metil)propil]carbámico, tetrahidro-3-furanil éster o un derivado fisiológicamente funcional de los mismos, zidovudina o un derivado fisiológicamente funcional de la misma, y (1S, 4R)-cis-4-[2-amino-6-(ciclopropilamino)- 9H-purin-9-il]-2-ciclo-penten-1-metanol o un derivado fisiológicamente funcional del mismo. Una combinación de acuerdo a la reivindicación 3, en donde la relación de ácido 3S-[3R* (1R* , 2S* )]- [3-[[(4-aminofenil)sulfonil](2-metilpropil)-amino]- 2-hidroxi-1-fenil-metil)propil]carbámico, tetrahidro-3-furanil éster, zidovudina: (1S, 4R)-cis-4-[2-amino-6-(ciclopropilamino)-9H- purin-9-il]-2-ciclopenten-1-metanol está en la relación de 1 a 20:1 a 20:1 a 10 en peso. Una combinación de acuerdo a cualquiera de las reivindicaciones 1 a 5 para usarse en terapia médica.
CO97034780A 1996-06-25 1997-06-23 Combinaciones antivirales CO4910137A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2217896P 1996-06-25 1996-06-25
GBGB9614024.9A GB9614024D0 (en) 1996-07-04 1996-07-04 Antiviral therapeutic combinations

Publications (1)

Publication Number Publication Date
CO4910137A1 true CO4910137A1 (es) 2000-04-24

Family

ID=26309631

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97034780A CO4910137A1 (es) 1996-06-25 1997-06-23 Combinaciones antivirales

Country Status (26)

Country Link
US (1) US6486136B1 (es)
EP (1) EP0910386B1 (es)
KR (1) KR20000022225A (es)
CN (1) CN1306430A (es)
AP (1) AP9801418A0 (es)
AT (1) ATE230267T1 (es)
AU (1) AU723877C (es)
BR (1) BR9709951A (es)
CA (1) CA2262765A1 (es)
CO (1) CO4910137A1 (es)
CZ (1) CZ429398A3 (es)
DE (1) DE69718168T2 (es)
EA (1) EA001457B1 (es)
ES (1) ES2189964T3 (es)
HU (1) HUP9903098A3 (es)
ID (1) ID18739A (es)
IL (1) IL127350A0 (es)
IS (1) IS4913A (es)
NO (1) NO986035L (es)
NZ (1) NZ333098A (es)
PE (1) PE87398A1 (es)
PL (1) PL330791A1 (es)
TR (1) TR199802703T2 (es)
WO (1) WO1997049410A1 (es)
YU (1) YU58498A (es)
ZA (1) ZA975565B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV

Also Published As

Publication number Publication date
IS4913A (is) 1998-11-30
YU58498A (en) 1999-11-22
AU723877C (en) 2001-08-23
BR9709951A (pt) 1999-08-10
ID18739A (id) 1998-05-07
EP0910386A1 (en) 1999-04-28
NZ333098A (en) 2000-08-25
AP9801418A0 (en) 1998-12-31
CN1306430A (zh) 2001-08-01
EA199801046A1 (ru) 1999-08-26
WO1997049410A1 (en) 1997-12-31
ATE230267T1 (de) 2003-01-15
HUP9903098A2 (hu) 1999-12-28
PE87398A1 (es) 1999-01-15
HU9903098D0 (en) 1999-10-28
AU3262697A (en) 1998-01-14
TR199802703T2 (xx) 1999-03-22
ES2189964T3 (es) 2003-07-16
US6486136B1 (en) 2002-11-26
AU723877B2 (en) 2000-09-07
CA2262765A1 (en) 1997-12-31
NO986035L (no) 1999-02-23
KR20000022225A (ko) 2000-04-25
DE69718168D1 (de) 2003-02-06
IL127350A0 (en) 1999-10-28
HUP9903098A3 (en) 2000-01-28
PL330791A1 (en) 1999-06-07
EA001457B1 (ru) 2001-04-23
CZ429398A3 (cs) 1999-05-12
EP0910386B1 (en) 2003-01-02
ZA975565B (en) 1998-12-23
NO986035D0 (no) 1998-12-22
DE69718168T2 (de) 2003-10-23

Similar Documents

Publication Publication Date Title
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
ES2087639T3 (es) Nucleosidos terapeuticos.
EA000626B3 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
MX9207382A (es) Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
PT97300A (pt) Processo para a preparacao de esteres de acidos 1,4-di-hidropiridinocarboxilicos n-alquilados e de medicamentos que os contem
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
CO4910137A1 (es) Combinaciones antivirales
NO986034L (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV
AR034059A1 (es) Producto que comprende mikanolido, dihidromikanolido o analogos de los mismos en combinacion con otro agente anticanceroso para uso terapeutico en el tratamiento del cancer
JO2032B1 (en) New salt (a chemical compound used to treat viral diseases)
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
MX9301746A (es) Nuevos acidos 9-fluor-7-oxo-7h-pirido(1,2,3,-de)(1,4)-benzoxacin-6-carboxilicos y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.
ES2130246T3 (es) Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
BR9814053A (pt) Diésteres lipofìlicos de agentes de quelação
ES2195158T3 (es) Amidas de alfa-aminoacidos, su preparacion y el uso terapeutico de las mismas.
MC1930A1 (fr) Produit antiviral
MX9401172A (es) Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2072332T3 (es) Derivados de la dibenzo(1,5)dioxocin-5-ona, su uso en medicamentos y procedimiento para su fabricacion.
AR007615A1 (es) Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene.
BR9810072A (pt) Formulação farmacêutica semi-sólida contendo dexcetoprofen trometamol
MX9303985A (es) Nucleosidos terapeuticos.